Skip to main content

Part of the book series: Methodological Surveys in Biochemistry and Analysis ((MSBA,volume 18 A))

  • 155 Accesses

Abstract

Pharmaceutical companies having their own R & D organization are increasingly confronted with the severe demands of the registration authorities. Besides the proof of safety and efficacy a third criterion is developing: a new drug in a given therapeutic area must be better than existing ones, in respect of therapeutic effect, fewer or no side-effects, or both criteria. This trend has led to the development of a number of rather potent drugs, having low dose regimes. Besides the implications for departments involved in synthesis and pharmacology, there are consequences for other disciplines such as analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Abbreviations

ECD:

electron-capture detection

FBz:

fluorobenzoic acid

PFB(B):

pentafluorobenzyl (bromide)

i.s.:

internal standard

t r :

retention time

References

  1. Ceelen, P.R.J., Ruijten, H.M. & de Bree, H. (1986) in Bioactive Analytes, including CNS Drugs, Peptides and Enantiomers [Vol. 16, this series] (Reid, E., Scales, B. & Wilson, I.D.), Plenum, N. York, p. 297.

    Google Scholar 

  2. Pearce, J.C., Jelly, J.A., Fernandes, K.A., Leavens, W.J. & McDowall, R.D. (1986) J. Chromatog. 353, 371–378.

    Article  CAS  Google Scholar 

  3. de Ridder, J.J., Koppens, P.C.J.M. & van Hal, H.J.M. (1977) J. Chromatog. 143, 281–287.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer Science+Business Media New York

About this chapter

Cite this chapter

de Bree, H. (1988). Analytical Consequences of Potent Drugs. In: Reid, E., Robinson, J.D., Wilson, I.D. (eds) Bioanalysis of Drugs and Metabolites, Especially Anti-Inflammatory and Cardiovascular. Methodological Surveys in Biochemistry and Analysis, vol 18 A. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9424-3_37

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-9424-3_37

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-9426-7

  • Online ISBN: 978-1-4757-9424-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics